Amgen Provides Update On Status Of Parsabiv(TM) (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)

THOUSAND OAKS, Calif., Aug. 24, 2016 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the New Drug Application (NDA) for Parsabiv (etelcal... Biopharmaceuticals, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2041531

Source: HSMN NewsFeed - August 25, 2016 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Hyperparathyroidism | Marketing | New Drug Applications | Pharmaceuticals